November 10, 2019 at 3:51 pm

Neos Therapeutics (NASDAQ:NEOS) Trading Up 11.7% Following Better-Than-Expected Earnings

by

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) were up 11.7% during trading on Friday following a stronger than expected earnings report. The company traded as high as $1.86 and last traded at $1.72, approximately 618,209 shares changed hands during mid-day trading. An increase of 91% from the average daily volume of 324,130 shares. The stock had previously closed at $1.54.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

The company reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. The firm had revenue of $17.54 million during the quarter.

NEOS has been the subject of a number of recent research reports. Zacks Investment Research cut Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 18th. ValuEngine raised Neos Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, BMO Capital Markets dropped their target price on Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating for the company in a report on Monday, August 12th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $6.10.

Several institutional investors and hedge funds have recently modified their holdings of NEOS. Stonepine Capital Management LLC lifted its stake in Neos Therapeutics by 10.2% in the second quarter. Stonepine Capital Management LLC now owns 4,971,014 shares of the company’s stock worth $6,413,000 after purchasing an additional 459,510 shares during the last quarter. Paloma Partners Management Co purchased a new stake in Neos Therapeutics in the second quarter worth about $275,000. Alambic Investment Management L.P. grew its holdings in Neos Therapeutics by 1,710.7% in the second quarter. Alambic Investment Management L.P. now owns 219,090 shares of the company’s stock worth $283,000 after purchasing an additional 206,990 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Neos Therapeutics by 1,790.7% in the second quarter. JPMorgan Chase & Co. now owns 215,900 shares of the company’s stock worth $261,000 after buying an additional 204,481 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Neos Therapeutics by 332.1% in the second quarter. Jane Street Group LLC now owns 165,503 shares of the company’s stock worth $213,000 after buying an additional 127,202 shares in the last quarter. 45.86% of the stock is owned by institutional investors and hedge funds.

The stock has a market cap of $76.58 million, a P/E ratio of -1.07 and a beta of 0.93. The firm’s 50 day moving average price is $1.49 and its 200-day moving average price is $1.62. The company has a debt-to-equity ratio of 41.70, a current ratio of 1.13 and a quick ratio of 0.91.

About Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Recommended Story: Day Trading

Leave a Comment

Your email address will not be published. Required fields are marked *